TP53 and myelodysplastic syndrome: A subsequent phase 2 study evaluated eprenetapropt (dosed at the recommended phase 2 dose of 100 mg/kg lean body mass (equivalent to 4500 mg/day fixed dosing) daily for four days each 28-day cycle, as identified in the phase 1b portion of the study) with azacitidine 75 mg/m2 on a 7-day schedule in patients with higher-risk MDS or oligoblastic (20–30% bone marrow blasts) AML with mutated TP53 [15].